Cardiovascular Disease and COVID-19: Insight From Cases With Heart Failure

• DOI: 10.3389/fcvm.2021.629958
• Publication Date: 2021-03-15T04:20:47Z
• Authors: Yang Yi; Yanan Xu; Haibing Jiang; Jun Wang
• Keywords: COVID-19; Cardiovascular Medicine; clinical outcomes; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; cardiovascular disease; Angiotensin (Ang)-converting enzyme 2; RC666-701; cardiac failure; Diseases of the circulatory (Cardiovascular) system; therapeutic strategies

Recent evidence indicates that a large proportion of deaths from coronavirus disease 2019 (COVID-19) can be attributed to cardiovascular disease, including acute myocardial infarction, arrhythmias and heart failure. Indeed, severe infection increases the risk failure among patients with COVID-19. In most patients, arises complex interactions between pre-existing conditions, cardiac injury, renin-angiotensin system activation, effects systemic inflammation on system. this review, we summarize current knowledge regarding pathogen-driven occurring during treatment for COVID-19, potential commonly used anti-infective drugs in these possible directions establishing theoretical basis clinical treatment.